Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $7.70 Analyst target: $13.50 Upside: 75.32%
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.